These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Portal and superior mesenteric venous thrombosis secondary to oral contraceptive treatment. Two cases (author's transl)].
    Author: Abet D, Pietri J.
    Journal: J Mal Vasc; 1982; 7(1):59-63. PubMed ID: 7077171.
    Abstract:
    Two new cases of superior mesenteric, portal and pulmonary venous thrombosis enable the authors to stress the close link between this pathology and the ingestion of oral contraceptives. The resultant vessel wall changes and laboratory changes are described. Whilst complete normalisation at the end of treatment is confirmed, preventive treatment will soon be possible by virtue of the development of new natural substances already perfected in the United States and the Scandinavian countries and recently marketed in our own country. About 28% of women aged 15-44 use oral contraceptives (OCs) in France. The 2 cases presented here, of superior mesenteric portal and pulmonary venous thrombosis in patients on uninterrupted OCs for 8 years, reconfirm the association between OCs and embolic pathology. Similar cases have been often described in the published literature. 3 main factors influence the induction of such thromboses; 1) modification of blood coagulation, 2) modification of the vessels' walls, and, 3) immunologic role of OCs. Blood coagulation is apparently modified by synthetic estrogens only, and not be progestin agents. The vessels' walls undergo a gradual thickening, together with a proliferation of the smooth muscular cells. On the immunologic plan, it is possible that OCs may cause the procreation of antiethinyl-estradiol antibodies which appear as circulating immune complexes. Thromboembolic risk disappears spontaneously after termination of OC treatment.
    [Abstract] [Full Text] [Related] [New Search]